Simulations Plus (SLP) to Release Earnings on Thursday

Simulations Plus (NASDAQ:SLP) is expected to post its quarterly earnings results after the market closes on Thursday, April 3rd. Analysts expect Simulations Plus to post earnings of $0.25 per share and revenue of $21.93 million for the quarter.

Simulations Plus Trading Down 1.7 %

Shares of NASDAQ SLP opened at $24.10 on Wednesday. The company’s 50-day moving average price is $30.54 and its 200 day moving average price is $30.42. Simulations Plus has a 52 week low of $23.44 and a 52 week high of $51.22. The stock has a market cap of $484.22 million, a price-to-earnings ratio of 60.25 and a beta of 0.89.

Insiders Place Their Bets

In other Simulations Plus news, Director Walter S. Woltosz sold 20,000 shares of Simulations Plus stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $33.91, for a total value of $678,200.00. Following the completion of the sale, the director now owns 3,402,584 shares in the company, valued at $115,381,623.44. The trade was a 0.58 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 19.40% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the company. William Blair reissued an “outperform” rating on shares of Simulations Plus in a report on Wednesday, January 8th. KeyCorp lifted their price objective on Simulations Plus from $35.00 to $37.00 and gave the stock an “overweight” rating in a research report on Friday, January 24th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $49.40.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.